In the winter of 2015,the first dengue vaccine(Dengvaxia)was approved for clinical use.Dengue virus is the most prevalent mosquito-transmitted viral pathogen in humans(Qin and Shi,2014).Even though the approved Dengva...In the winter of 2015,the first dengue vaccine(Dengvaxia)was approved for clinical use.Dengue virus is the most prevalent mosquito-transmitted viral pathogen in humans(Qin and Shi,2014).Even though the approved Dengvaxia has its weaknesses(e.g.,low protection against serotype-2virus),it has been recently licensed to Mexico,Philippines,展开更多
基金Chengfeng Qin was supported by the Excellent Young Scientist Program of the National Natural Science Foundation (81522025)XF Li was supported by the Beijing Nova Program of Science & Technology (2016110)
文摘In the winter of 2015,the first dengue vaccine(Dengvaxia)was approved for clinical use.Dengue virus is the most prevalent mosquito-transmitted viral pathogen in humans(Qin and Shi,2014).Even though the approved Dengvaxia has its weaknesses(e.g.,low protection against serotype-2virus),it has been recently licensed to Mexico,Philippines,
